Media coverage about Hill-Rom (NYSE:HRC) has trended somewhat positive on Sunday, Accern Sentiment reports. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Hill-Rom earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned news coverage about the medical technology company an impact score of 46.5857183180534 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the headlines that may have effected Accern Sentiment’s analysis:
Shares of Hill-Rom (HRC) traded down $0.17 during midday trading on Friday, hitting $86.79. The stock had a trading volume of 693,352 shares, compared to its average volume of 359,446. The company has a debt-to-equity ratio of 1.55, a quick ratio of 1.34 and a current ratio of 1.77. Hill-Rom has a 12-month low of $57.18 and a 12-month high of $88.91. The stock has a market capitalization of $5,712.60, a P/E ratio of 22.48, a price-to-earnings-growth ratio of 1.55 and a beta of 1.19.
Hill-Rom (NYSE:HRC) last issued its quarterly earnings results on Friday, November 3rd. The medical technology company reported $1.32 earnings per share for the quarter, topping the consensus estimate of $1.27 by $0.05. Hill-Rom had a return on equity of 20.27% and a net margin of 4.87%. The firm had revenue of $738.30 million for the quarter, compared to the consensus estimate of $731.10 million. During the same period in the prior year, the business posted $1.18 earnings per share. The company’s revenue for the quarter was up 4.6% on a year-over-year basis. research analysts expect that Hill-Rom will post 4.32 EPS for the current year.
The firm also recently declared a quarterly dividend, which was paid on Friday, December 29th. Stockholders of record on Friday, December 15th were issued a $0.18 dividend. The ex-dividend date of this dividend was Thursday, December 14th. This represents a $0.72 annualized dividend and a dividend yield of 0.83%. Hill-Rom’s payout ratio is 36.18%.
A number of equities analysts recently commented on the company. Zacks Investment Research raised Hill-Rom from a “sell” rating to a “hold” rating in a research note on Monday, September 18th. ValuEngine lowered Hill-Rom from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Raymond James Financial raised Hill-Rom from a “market perform” rating to an “outperform” rating and set a $94.00 price target for the company in a research note on Wednesday, January 3rd. Barclays increased their price target on Hill-Rom from $86.00 to $90.00 and gave the company an “overweight” rating in a research note on Monday, November 6th. Finally, Bank of America reaffirmed a “hold” rating on shares of Hill-Rom in a research note on Wednesday, November 22nd. Six equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $93.00.
In other Hill-Rom news, CEO John J. Greisch sold 125,241 shares of the firm’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $82.59, for a total transaction of $10,343,654.19. Following the transaction, the chief executive officer now directly owns 280,851 shares in the company, valued at approximately $23,195,484.09. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Paul Sherwood Johnson sold 1,000 shares of the firm’s stock in a transaction on Wednesday, December 13th. The stock was sold at an average price of $82.99, for a total value of $82,990.00. Following the transaction, the senior vice president now owns 1,066 shares in the company, valued at $88,467.34. The disclosure for this sale can be found here. Over the last quarter, insiders sold 226,241 shares of company stock worth $18,708,644. Company insiders own 2.20% of the company’s stock.
WARNING: This story was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/14/hill-rom-hrc-receiving-somewhat-positive-media-coverage-study-shows.html.
Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.